First Human Dosing of Gerilimzumab
RuiYi initiates clinical trial for autoimmune disorders drug
arGEN-X licensed the worldwide rights to develop and commercialize Gerilimzumab to RuiYi in late 2012. Gerilimzumab was originally generated by arGEN-X using its SIMPLE Antibody™ platform and has been further differentiated with NHance®, its novel, proprietary technology, which prolongs the circulation time and improves tissue distribution of antibodies.
The clinical trial initiated by RuiYi is a double-blind, placebo controlled study in healthy volunteers, with both single and multiple ascending dose protocols. The start of the trial triggers an undisclosed milestone payment by RuiYi to arGEN-X.
Positive results from this study will support advancing Gerilimzumab into trials in patients with autoimmune disorders, including moderate to severe rheumatoid arthritis in 2016.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.